Western Hemisphere
K2 Therapeutics Names Ex-Legend Biotech CEO Ying Huang and Announces $50M Seed Financing
K2 Therapeutics announced on August 11 that it has appointed Dr. Ying Huang as chief executive officer and closed US$50 million in seed financing from MPM BioImpact, the life sciences investment firm that founded the company in 2024. K2 operates from Boston and Singapore and is chaired by Ansbert